HUTCHMED to Announce 2025 Final Results
HUTCHMED (Nasdaq/AIM: HCM; SEHK:13) will announce its final results for the year ended December 31, 2025 on Thursday, March 5, 2026.
Rhea-AI Summary
HUTCHMED (Nasdaq/AIM: HCM; SEHK:13) will announce its final results for the year ended December 31, 2025 on Thursday, March 5, 2026.
Management will host two webcast presentations for analysts and investors with Q&A. The English webcast is at 8:00 am EST and the Chinese (Putonghua) webcast at 8:30 am HKT. Slides and replays will be available via the company website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – HCM
In the Feb 6 session, HCM gained 4.19%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Results date
- March 5, 2026
- Final results for year ended December 31, 2025
- Results release time
- 6:00 am EST
- Final results announcement on March 5, 2026
- English webcast time
- 8:00 am EST
- Analyst/investor webcast on March 5, 2026
- Chinese webcast time
- 8:30 am HKT
- Putonghua webcast on March 6, 2026
Historical Context
-
Publication of SACHI Phase III savolitinib+osimertinib results in The Lancet.
-
Phase III ESLIM-02 sovleplenib trial met primary endpoint in wAIHA.
-
Initiation of Phase III stage of surufatinib combo trial in pancreatic cancer.
-
China NMPA accepted savolitinib NDA with priority review for gastric cancer.
-
China NMPA accepted fanregratinib NDA with priority review for ICC.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).
Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/. The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
